Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

NCT05456048 · clinicaltrials.gov ↗

COMPLETED

Status

231

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Gene Abnormality
Cytogenetic Abnormality

Interventions

DRUG: VAH regimen
DRUG: VEN+HMA regimen

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]